OSI Pharmaceuticals (OSIP) - formerly Oncogene Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (91)	2/17/2000 7:32:00 PM
From: Miljenko Zuanic	Read Replies (2) of 447

Just parking (competative development); biz.yahoo.com <<Biogen and CV Therapeutics Say Adenosine A1 Antagonist Is Successful in a Phase II Trial CAMBRIDGE, Mass., and PALO ALTO, Calif., Feb. 17 /PRNewswire/ -- Biogen, Inc. (Nasdaq: BGEN - news) and CV Therapeutics, Inc. (Nasdaq: CVTX - news) today announced that Biogen's adenosine A1 antagonist/CVT-124 compound successfully completed a Phase II trial in patients with moderate-to-severe Congestive Heart Failure (CHF). Biogen said it would continue studies with its lead backup molecule. (snip> Good news for target validation, good news for science, too bad that BGEN have to go back for backup compound. <g> Now YEASTGENE/Solvay will have chance to advance and maybe be ahead of them. <<In addition, an A(1) targeted compound, CDS-096370, has potential for use in the treatment of congestive heart failure and renal failure. This candidate has been licensed to Solvay for advanced pre-clinical and clinical development.>> GO KDUS, GO! Miljenko.endo

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next